A Phase I first in human study, evaluating EVO756 in heathy adults and adults with chronic spontaneous urticaria (CSU)
Latest Information Update: 09 Dec 2024
At a glance
- Drugs EVO 756 (Primary)
- Indications Chronic urticaria
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Evommune
Most Recent Events
- 04 Dec 2024 According to an Evommune media release, data from this trial presented at the 7th GALEN Global Urticaria Forum in Berlin, Germany.
- 04 Dec 2024 Results published in the Evommune Media Release
- 04 Dec 2024 Status changed from recruiting to completed as per Evommune media release